Recent Press Releases

North Carolina-based collaboration takes on medicine management challenge

North Carolina-based collaboration takes on medicine management challenge Organizations focus on role of pharmacists in lowering health care costs, improving health outcomes RALEIGH, NC, October 30,...

Bayer operationally strong – strategic focus on Life Science businesses

Sales advance in all subgroups – double-digit percentage growth for CropScience and the Pharmaceuticals Division (Fx & portfolio adj.) / Group sales EUR 10,187 million (plus 5.6 percent /...

Novo Nordisk now hiring for new manufacturing facility in New Hampshire

Novo Nordisk now hiring for new manufacturing facility in New Hampshire WEST LEBANON, N.H., Oct. 29, 2014 /PRNewswire/ -- Novo Nordisk, a global pharmaceutical company that produces medicines for...

Teva Reports Third Quarter 2014 Results

Teva Reports Third Quarter 2014 Results Revenues of $5.1 billion, in line with the third quarter of 2013. Excluding the impact of the divestment of the U.S. OTC plants and of foreign exchange...

US FDA APPROVES ONCE-DAILY XIGDUO™ XR TABLETS FOR ADULTS WITH TYPE 2 DIABETES

US FDA APPROVES ONCE-DAILY XIGDUO™ XR TABLETS FOR ADULTS WITH TYPE 2 DIABETES First US approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release 30 October...

AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014

AMAG Pharmaceuticals Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014 20% Growth Results in Record U.S. Feraheme Sales Lumara Health Acquisition on Track to Close...

Lilly Shares Insights from Decade-Long Technology Transfer Experience

New white paper documents Lilly's philanthropic effort to expand access to multidrug-resistant tuberculosis medicines

INDIANAPOLIS

Gilead Sciences Announces Third Quarter 2014 Financial Results

Gilead Sciences Announces Third Quarter 2014 Financial Results Product Sales of $5.97 billion - - Sovaldi Sales of $2.80 billion - - Non-GAAP EPS of $1.84 per share - - Revised 2014 Full Year...

Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans

Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018

NEW YORK,

Allergan Reports Third Quarter 2014 Operating Results

(IRVINE, Calif., October 27, 2014) - Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended September 30, 2014. Allergan also announced that its Board of Directors has...

Universal Health Services, Inc. Reports Financial Results For The Three And Nine Months Ended September 30, 2014

Consolidated Results of Operations, As Reported - Three and nine-month periods ended September 30, 2014 and 2013:

KING OF PRUSSIA, Pa.

Assistance Programs, Dividends, Campaigns, Drug Recommendations, and Research Collaborations - Research Reports on Duke Energy, Exelon, Marriott, Vertex and AstraZeneca

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 27, 2014

DURECT Provides Update on REMOXY® and POSIDUR™ Programs

CUPERTINO, Calif., Oct.

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD...